GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rafarma Pharmaceuticals Inc (OTCPK:RAFA) » Definitions » Forward PE Ratio

Rafarma Pharmaceuticals (Rafarma Pharmaceuticals) Forward PE Ratio : 0.00 (As of Jun. 25, 2024)


View and export this data going back to . Start your Free Trial

What is Rafarma Pharmaceuticals Forward PE Ratio?

Rafarma Pharmaceuticals's Forward PE Ratio for today is 0.00.

Rafarma Pharmaceuticals's PE Ratio without NRI for today is 9999.00.

Rafarma Pharmaceuticals's PE Ratio for today is 9999.00.


Rafarma Pharmaceuticals Forward PE Ratio Historical Data

The historical data trend for Rafarma Pharmaceuticals's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rafarma Pharmaceuticals Forward PE Ratio Chart

Rafarma Pharmaceuticals Annual Data
Trend
Forward PE Ratio

Rafarma Pharmaceuticals Quarterly Data
Forward PE Ratio

Competitive Comparison of Rafarma Pharmaceuticals's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Rafarma Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rafarma Pharmaceuticals's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rafarma Pharmaceuticals's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Rafarma Pharmaceuticals's Forward PE Ratio falls into.



Rafarma Pharmaceuticals Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Rafarma Pharmaceuticals  (OTCPK:RAFA) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Rafarma Pharmaceuticals Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Rafarma Pharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rafarma Pharmaceuticals (Rafarma Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
12465 Sourth Fort Street, Draper, UT, USA, 84020
Rafarma Pharmaceuticals Inc manufactures and distributes colloidal systems, fine chemistry, pharmaceutical substances, pharmaceutical development, new drugs, pharmaceutical packaging, and other technologies in the field of biotechnology in Europe and Asia.

Rafarma Pharmaceuticals (Rafarma Pharmaceuticals) Headlines

From GuruFocus

Letter to Shareholders from the Chairman of the Board Ilya Shpurov

By Marketwired Marketwired 08-10-2021

Rafarma to be Acquired by R. & D. Biocogency Laboratories Inc.

By Marketwired Marketwired 08-04-2020

Rafarma's Global Pharmaceutical Strategy At A Glance

By Marketwired Marketwired 05-18-2021

Rafarma Finalizes Announces New Product

By Marketwired Marketwired 06-15-2020

Explosive Growth Launches Kraspharma Into REMEDIUM TOP-5

By GuruFocusNews GuruFocusNews 11-19-2021

RAFA To Add Major Component to the Tashkent Pharma Park

By GuruFocusNews GuruFocusNews 12-17-2021